Through the use of artificial intelligence (AI) and imaging modalities such as ultrasound, CT, and MRI, the newly FDA-cleared VisAble.IO software reportedly enhances planning and real-time assessment for liver tumor ablation procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for VisAble.IO (TechsoMed), an artificial intelligence (AI)-enabled software that may facilitate improved real-time imaging guidance — through ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI) — for liver tumor ablation procedures.
TechsoMed said the software’s advanced computation and image registration elevate the planning and real-time assessment of liver tumor ablation.
The company noted that key benefits of the VisAble.IO software include:
• three-dimensional (3D) anatomical views of ablation targets;
• overlay positioning of virtual instruments and ablation region estimates onto imaging; and
• immediate post-procedure 3D views to assess ablation margins and potentially missed volumes.
“There is a real need for a good and efficient assessment tool, and (VisAble.IO) can serve any physician performing thermal ablations,” noted Ryosuke Tateishi, M.D., Ph.D., an associate professor in the Department of Gastroenterology at the University of Tokyo.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.